HQY
HealthEquity, Inc.
HQY offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has a slight edge over HQY overall, supported by stronger modeled upside and stronger fundamentals.
HQY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
HQY's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HQY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $103 | — |
| Current | 37x | $103 | — |
| Cheap | 41x | $112 | +9% |
| Fair | 87x | $242 | +135% |
| Expensive | 1,293x | $3,580 | +3374% |
Historical ranges are pointers, not guarantees.
HQY has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HQY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HQY, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HQY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.23 | +89% |
| Q3 2026 | $2.77 | +68% |
| Q2 2026 | $2.67 | +95% |
| Q1 2026 | $2.46 | +126% |
| Q4 2025 | $2.18 | +100% |
| Q3 2025 | $1.65 | +38% |
| Q2 2025 | $1.37 | +49% |
| Q1 2025 | $1.09 | +70% |
| Q4 2024 | $1.09 | +221% |
HQY's earnings per share have climbed steadily: $2.77 over the past year, up 68% from the year before, and higher year over year for 15 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HQY on earnings, with stronger typical year-over-year growth.
HQY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.7M | +7.6% |
| Q2 2026 | $354.6M | +7.2% |
| Q1 2026 | $334.6M | +7.3% |
| Q4 2025 | $322.2M | +7.2% |
| Q3 2025 | $325.8M | +8.6% |
| Q2 2025 | $330.8M | +15% |
| Q1 2025 | $311.8M | +19% |
| Q4 2024 | $300.4M | +21% |
HQY's revenue has grown year over year for 21 quarters in a row: $351M last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +0.6 points |
| Q2 2026 | 29% | +3.9 points |
| Q1 2026 | 21% | +7.7 points |
| Q4 2025 | 24% | +18 points |
| Q3 2025 | 28% | +7.9 points |
| Q2 2025 | 25% | +11 points |
| Q1 2025 | 14% | -1.3 points |
| Q4 2024 | 6.5% | -5.9 points |
HQY's operating margin was 28% last quarter, up 0.6 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HQY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HQY on profitability, with a higher operating margin.
HQY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $135.2M | +0.1% |
| Q2 2026 | $97.2M | +50% |
| Q1 2026 | $117.6M | +56% |
| Q4 2025 | $137.8M | +53% |
| Q3 2025 | $135.1M | +26% |
| Q2 2025 | $64.7M | -0.1% |
| Q1 2025 | $75.4M | -1.4% |
| Q4 2024 | $90.3M | +60% |
HQY's free cash flow has been positive every quarter for seven years: $488M over the past year, up 33% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
HQY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -992K shares |
| 1 year | -4.3% | -3.7M shares |
| 3 years | -2.7% | -2.3M shares |
| 5 years | +0.6% | +533K shares |
| Available history | +19% | +13.5M shares |
HQY has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $107.7M |
| Q2 2026 | $123.3M |
| Q1 2026 | $81M |
| Q4 2025 | $92.4M |
| Q3 2025 | $66.7M |
| Q2 2025 | $59.1M |
| Q1 2025 | $63M |
HQY spent $404M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HQY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.3x | Healthy |
| Q2 2026 | 1.4x | Healthy |
| Q1 2026 | 1.3x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.4x | Moderate |
HQY's net debt is about 1.3 years of its operating earnings (EBITDA), down from 1.8 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over HQY on leverage, with a lower net debt burden relative to earnings.
HQY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 73.0 | Neutral |
HQY's weekly RSI is 60 (neutral) and its Stochastic is 73 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HQY PE vs Healthcare Sector
| Metric | HQY | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 44% above |
| PE % | 13 | 29 | 16 pts below |
HQY has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HQY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.0 | 6.2% above |
| 20 week MA | $97.9 | 5.3% above |
| 50 week MA | $90.3 | 14% above |
| 100 week MA | $93.5 | 10% above |
| 200 week MA | $83.2 | 24% above |
HQY is in an uptrend: it's above all five of its weekly moving averages, and 24% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
HQY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.0 | $68.3 | -7.7% |
| 2021 | $68.3 | $44.9 | -34% |
| 2022 | $44.9 | $61.6 | +37% |
| 2023 | $61.6 | $66.3 | +7.6% |
| 2024 | $66.3 | $96.3 | +45% |
| 2025 | $96.3 | $93.5 | -2.9% |
| 2026 YTD | $93.5 | $103.1 | +10% |
HQY has finished lower in three of the last six years. It's up 10% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HQY on returns for 2026, with the stronger performance.